
Sight Sciences (SGHT) Stock Forecast & Price Target
Sight Sciences (SGHT) Analyst Ratings
Bulls say
Sight Sciences Inc. exhibits a positive outlook due to the potential for stronger revenue growth, driven by faster-than-expected market share gains in the Minimally Invasive Glaucoma Surgery (MIGS) sector and quicker adoption of the TearCare System. The company's investment thesis highlights the capability of its Surgical Glaucoma business to sustain growth in alignment with the overall MIGS market. Additionally, the upward revision of earnings per share (EPS) forecasts for 2025 and 2026, moving to ($1.04) and ($0.88) respectively, points towards improving financial performance as the company progresses towards profitability.
Bears say
Sight Sciences Inc. has reiterated its 2025 revenue guidance of $72-76 million while also forecasting a mid-single-digit year-over-year decline in Surgical Glaucoma revenue for the third quarter of 2025. The company faces significant risks, including rising competition in the minimally invasive glaucoma surgery (MIGS) sector, delays in obtaining insurance coverage for its TearCare product, and ongoing issues with cash burn. Furthermore, although management has adjusted its 2025 operating expense guidance downward to $95-99 million, the reduced expenses are unlikely to offset the overall revenue challenges and competitive pressures the company is encountering.
This aggregate rating is based on analysts' research of Sight Sciences and is not a guaranteed prediction by Public.com or investment advice.
Sight Sciences (SGHT) Analyst Forecast & Price Prediction
Start investing in Sight Sciences (SGHT)
Order type
Buy in
Order amount
Est. shares
0 shares